Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes
- 12 August 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (10) , 1179-1194
Abstract
1. Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell malignancy distinguished by the Philadelphia (Ph) chromosome, which results from an unbalanced reciprocal translocation of chro...Keywords
Funding Information
- Azurity Pharmaceuticals Inc
This publication has 92 references indexed in Scilit:
- Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE StudyHematological Oncology, 2025
- Management of chronic myeloid leukemia in 2025Cancer, 2025
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology, 2024
- Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaCancer, 2023
- Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort studyAnnals of Hematology, 2020
- Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinibEuropean Journal of Clinical Pharmacology, 2020
- Effects of breast cancer on chronic disease medication adherence among older womenPharmacoepidemiology and Drug Safety, 2016
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEuropean Journal of Clinical Pharmacology, 2011
- First‐line therapy for chronic myeloid leukemia: Past, present, and futureAmerican Journal of Hematology, 2009
- ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIAJAMA, 1931